Sonesitatug vedotin cuts risk of death 42% in CLDN18.2-positive advanced gastric cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this setting WILMINGTON, Del., October 25, 2026--(BUSINESS WIRE)--Positive…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase III data from AstraZeneca in gastric oncology can strengthen the group's pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The CLARITY-Gastric01 study reached statistical significance on overall survival in second-line and later treatment.
- 02Sonesitatug vedotin was compared with investigator's choice of therapy.
- 03The population includes gastric, GEJ and esophageal adenocarcinoma with CLDN18.2 expression on at least 25% of tumor cells.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets